Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
PRNewswire (Thu, 4-Dec 4:05 PM ET)
Virax Biolabs Group Limited Announces $5 Million Private Placement
PRNewswire (Wed, 3-Dec 1:54 PM ET)
VRAX’s Cash Surpasses Market Value: Virax Biolabs Sets 2026 Milestones After Major Clinical Progress
Market Chameleon (Wed, 3-Dec 4:51 AM ET)
PRNewswire (Wed, 3-Dec 7:34 AM ET)
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
Virax Biolabs Group Limited - trades on the NASDAQ stock market under the symbol VRAX.
As of December 19, 2025, VRAX stock price was flat at $0.39 with 138,970 million shares trading.
VRAX has a beta of 1.89, meaning it tends to be more sensitive to market movements. VRAX has a correlation of 0.14 to the broad based SPY ETF.
VRAX has a market cap of $1.69 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, VRAX traded as high as $16.00 and as low as $.35.
VRAX has underperformed the market in the last year with a price return of -79.4% while the SPY ETF gained +18.1%. VRAX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -38.0% and -38.1%, respectively, while the SPY returned +2.8% and -0.5%, respectively.
VRAX support price is $.35 and resistance is $.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRAX shares will trade within this expected range on the day.
